

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**  
**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Tolvaptan for treating autosomal dominant polycystic kidney disease**

**Batch 31**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- 1) Consultees and attendees suggested that some ethnic groups are known to access chronic kidney disease services later, especially transplant services.
- 2) Consultees requested consideration of prescribing of tolvaptan in children in the appraisal.
- 3) A consultee noted that individuals with ADPKD with predominantly liver symptoms may be prejudiced against in not meeting specific criteria with regards to stages of chronic kidney disease, and that liver cysts occur more commonly in women.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- 1) The attendees agreed that the issue of ethnic groups accessing services later was not specific to ADPKD patients. This is not a specific equalities issue associated with access to treatment with tolvaptan and is therefore not considered to be an equalities issue that can be addressed by the recommendations in this technology appraisal.

- 2) NICE can only appraise a technology in accordance with its marketing authorisation. The population considered by the Committee in this appraisal will therefore be determined by the wording in the marketing authorisation for tolvaptan. It is anticipated that the marketing authorisation will reflect the population in the clinical trials, that is, adults.
- 3) The Committee will consider the evidence presented by stakeholders in line with the marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

**Approved by Associate Director (name):** Helen Knight

**Date:** 21 October 2014